Cummings SR, et al. - The risk of new or worsening vertebral fractures was examined in participants who discontinued denosumab during the FREEDOM study or its Extension, especially multiple vertebral fractures. Multiple vertebral fractures were observed in a majority of participants who sustained a vertebral fracture after discontinuing denosumab, with the greatest risk in participants with a prior vertebral fracture. Thus, patients who discontinue denosumab ought to rapidly transition to an alternative antiresorptive treatment.